Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the pharmacy business, higher prescription prices and increased long-term care insurance revenue were offset by a decline in the number of prescriptions handled and higher personnel expenses, which put pressure on profit. The BPO business benefited from an increase in the number of dispatched medical representatives, expansion of contracted services related to occupational physicians and occupational health nurses, and strong performance in the materials production business. The pharmaceutical business benefited from the launch of new products and cost reductions for existing products.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥145,808 million (YoY +2.5%) |
| Operating profit | ¥10,369 million (YoY +44.4%) |
| Ordinary income | ¥10,353 million (YoY +42.7%) |
| Profit attributable to owners of the parent | ¥4,675 million (YoY +31.8%) |
| Net income per share | ¥125.54 |
| Equity ratio | End of the current fiscal period 37.1 / End of previous period 36.3 |
| Total assets | ¥159,369 million |
| Net assets | ¥61,464 million |
| Cash flows from operating activities | ¥6,751 million |
| Cash flows from investing activities | ¥-1,893 million |
| Cash flows from financing activities | ¥-5,611 million |
| Cash and cash equivalents at end of period | ¥20,235 million |
| Full-year earnings forecast | Net Sales ¥315,000 million (YoY +8.3%) / Operating profit ¥16,500 million (YoY +11.4%) / Ordinary income ¥16,500 million (YoY +10.9%) / Net income ¥7,800 million (YoY +5.3%) |
| Revision to Earnings Forecast | No change |
| Annual Dividend Forecast | ¥50 → ¥64（+28.0%） |
| Segment revenue | Pharmacy business ¥88,357 million (YoY +1.9%), BPO business ¥7,582 million (YoY +7.5%), Pharmaceutical business ¥49,867 million (YoY +2.9%) |
| Segment profit | Pharmacy business ¥3,609 million (YoY -10.9%), BPO business ¥1,139 million (YoY +13.7%), Pharmaceutical business ¥7,750 million (YoY +91.7%) |
| Depreciation and amortization | ¥3,064 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of property, plant and equipment ¥30 million, Other ¥2 million / Extraordinary loss Loss on disposal of property, plant and equipment ¥19 million, Loss on sale of property, plant and equipment ¥0 million, Loss on contract cancellation ¥279 million, Other ¥7 million |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | In October 2026, the Company acquired shares of 株式会社メディカメンテ and 株式会社MY. In November 2026, it entered into an exclusive distribution and supply agreement in Japan for aflibercept BS products and plans to launch an emergency contraceptive. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 38,902,785 shares |
| Treasury Shares at Period-End | 2,268,219 shares |
| Factors Behind Changes in Business Performance | In the pharmacy business, higher prescription prices and increased long-term care insurance revenue were offset by a decline in the number of prescriptions handled and higher personnel expenses, which put pressure on profit. The BPO business benefited from an increase in the number of dispatched medical representatives, expansion of contracted services related to occupational physicians and occupational health nurses, and strong performance in the materials production business. The pharmaceutical business benefited from the launch of new products and cost reductions for existing products. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the pharmacy business, higher prescription prices and increased long-term care insurance revenue were offset by a decline in the number of prescriptions handled and higher personnel expenses, resulting in lower operating profit. In the BPO business, results benefited from an increase in the number of dispatched medical representatives, expansion of contracted services related to occupational physicians and occupational health nurses, and strong performance in the materials production business. In the pharmaceutical business, the launch of new products and cost reductions for existing products made significant contributions.